Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
F 0.58 4.24% 0.02
AGEN closed up 4.24 percent on Thursday, March 28, 2024, on 52 percent of normal volume.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
NR7 Range Contraction 4.24%
Narrow Range Bar Range Contraction 4.24%
Inside Day Range Contraction 4.24%
Wide Bands Range Expansion 4.24%
180 Bearish Setup Bearish Swing Setup 8.13%
Wide Bands Range Expansion 8.13%
Gapped Up Strength 8.13%
NR7 Range Contraction 3.87%
Narrow Range Bar Range Contraction 3.87%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 18 hours ago
Possible NR7 about 20 hours ago
10 DMA Support 1 day ago
Down 1% 1 day ago
Rose Above Previous Day's High 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Agenus Inc. Description

Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Infectious Diseases Alzheimer's Disease Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Vaccines Vaccination Carcinoma Malaria Glioma Herpes Renal Cell Carcinoma Shingles Cancer Vaccine Experimental Cancer Treatments Metastatic Melanoma Agenus Genital Herpes Treatment Of Malaria

Is AGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.13
52 Week Low 0.485
Average Volume 10,560,968
200-Day Moving Average 1.02
50-Day Moving Average 0.65
20-Day Moving Average 0.61
10-Day Moving Average 0.55
Average True Range 0.06
RSI (14) 44.44
ADX 17.59
+DI 18.17
-DI 21.02
Chandelier Exit (Long, 3 ATRs) 0.62
Chandelier Exit (Short, 3 ATRs) 0.66
Upper Bollinger Bands 0.73
Lower Bollinger Band 0.49
Percent B (%b) 0.38
BandWidth 40.51
MACD Line -0.04
MACD Signal Line -0.03
MACD Histogram -0.0023
Fundamentals Value
Market Cap 221.27 Million
Num Shares 381 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 2.83
Price-to-Book 218.61
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.62
Resistance 3 (R3) 0.62 0.60 0.62
Resistance 2 (R2) 0.60 0.59 0.60 0.61
Resistance 1 (R1) 0.59 0.58 0.59 0.59 0.61
Pivot Point 0.57 0.57 0.57 0.57 0.57
Support 1 (S1) 0.56 0.56 0.57 0.57 0.55
Support 2 (S2) 0.54 0.55 0.54 0.55
Support 3 (S3) 0.53 0.54 0.54
Support 4 (S4) 0.54